Source comparison
Sermorelin vs HGH Therapy: Complete Comparison
Mechanism GHRH analog. Stimulates pituitary GH release Exogenous recombinant hormone. Replaces endogenous GH Sermorelin requires functional pituitary; HGH does not GH Release Pattern Pulsatile (mimics natural rhythm) Sustained elevation (8–12 hours) Sermorelin
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH analog. Stimulates pituitary GH release
- Exogenous recombinant hormone. Replaces endogenous GH
- Sermorelin requires functional pituitary; HGH does not
- GH Release Pattern
- Pulsatile (mimics natural rhythm)
- Sustained elevation (8–12 hours)
- Sermorelin preserves circadian regulation; HGH overrides it
- FDA Approval Status
- Diagnostic use only (off-label for therapy)
- Approved for GH deficiency, Turner syndrome, short bowel syndrome, others
- HGH has broader therapeutic indications but stricter prescribing oversight
- Typical Dose
- 200–500 mcg/day subcutaneous
- 0.2–0.5 mg/day therapeutic; 2–4 IU/day off-label
- Sermorelin doses are fixed; HGH doses vary widely by indication
- Cost (monthly)
- $150–$300 (compounded)
- $800–$1,500 (brand); $400–$700 (compounded)
- Sermorelin is 3–5× less expensive than branded HGH
- Pituitary Suppression Risk
- None. Works through natural feedback
- High. Exogenous GH suppresses endogenous production
- Sermorelin stops cleanly; HGH may require tapering
- Side Effect Frequency
- 10–15% (injection site, flushing)
- 20–30% (edema, joint pain, insulin resistance)
- HGH has a broader and more severe adverse event profile